FDA Brief

Warning letters Drugs

FDA warning letter to

Heaven’s Organic LLC

High riskIssued Mar 28, 2022Posted Mar 29, 2022Center for Drug Evaluation and Research | CDER

FDA and FTC warned Heaven’s Organic LLC over CBD products sold with unapproved COVID-19 treatment and prevention claims.

What happened

FDA and FTC reviewed Heaven’s Organic’s website on February 15, 2022, and March 9, 2022, respectively, plus Facebook, Instagram, and Twitter pages that directed consumers to the website. FDA found CBD products offered for sale with claims that they could mitigate, prevent, treat, diagnose, or cure COVID-19, including January 25, 2022 social media posts saying CBD could fight COVID-19. No inspection is mentioned; the letter is based on website and social media review.

What FDA found

  1. FDA says the CBD products are unapproved new drugs because the company presents them as COVID-19 treatments or preventives without FDA approval.

    section 505(a) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(a)
  2. FDA says the products are misbranded drugs because their labeling makes drug claims without meeting the required drug labeling rules.

    section 502 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 352
  3. FDA says selling these unapproved and misbranded drugs across state lines is prohibited.

    sections 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 331(a) and (d)
  4. The FTC says the company advertised that the products can prevent, treat, or cure COVID-19 without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. § 41 et seq.
  5. The FTC says deceptive COVID-19 treatment, cure, prevention, or mitigation claims can lead to civil penalties under the COVID-19 Consumer Protection Act.

    COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260

What FDA wants

FDA asks the company to stop selling unapproved COVID-19 products immediately and, within 48 hours, email FDA describing corrective steps with documentation, or explain why it cannot and give a timeline. FTC also asks for certification within 48 hours that unsubstantiated claims have stopped.

Who should pay attention

  • CBD brands that make health claims
  • online retailers selling CBD products
  • marketers using social media for disease claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Trew Balance

    FDA warned Trew Balance that its Trew Vision CBD Eye Drops are an unapproved new drug sold with disease-treatment claims.

    High risk
  2. Bailey’s Wellness, LLC dba Bailey’s CBD

    Bailey’s CBD markets CBD animal and human products with unapproved drug claims, including products for food-producing animals.

    High risk
  3. House of Alchemy LLC dba CBD Dog Health Hamet & Love LLC dba MycoDog

    FDA warned CBD Dog Health and MycoDog their CBD and mushroom pet products are unapproved animal drugs, citing disease-treatment claims online.

    High risk
  4. Holista LLC dba HolistaPet

    FDA warned HolistaPet that its CBD animal products are unapproved new animal drugs and adulterated animal food.

    High risk